SMS Pharmaceuticals Lists 5 Crore Equity Shares from Warrant Conversion on BSE and NSE

SMS Pharmaceuticals Limited has successfully listed 5 crore (50,00,000) new equity shares on both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE). This listing marks a significant corporate action for the pharmaceutical company, stemming from the conversion of warrants previously issued to promoters.

Key Details of the Listing

Aspect	Details
Number of Shares	50,00,000
Face Value	Re. 1 per share
Premium	Rs. 126 per share
Total Issue Size	5 crore shares
Allotment Type	Preferential basis to promoters
Trading Commencement	November 7, 2025
Distinctive Numbers	88652031 to 93652030
Lock-in Period	Until October 30, 2027

Significance of the Move

This equity expansion through warrant conversion demonstrates SMS Pharmaceuticals' strategic approach to capital structuring. The preferential allotment to promoters suggests a strong commitment from the company's leadership, potentially indicating confidence in the firm's future prospects.

Regulatory Compliance

The company has meticulously followed regulatory procedures, securing necessary approvals from both BSE and NSE. This adherence to compliance standards ensures transparency in the listing process, which is crucial for maintaining investor trust.

Impact on Shareholding

With the addition of these new shares, SMS Pharmaceuticals' equity base has expanded. This move may have implications for the company's shareholding pattern, particularly increasing the promoter stake. Investors and market analysts will likely be keen to observe how this impacts the company's financial metrics and market perception.

Lock-in Period Consideration

It's noteworthy that these newly listed shares come with a lock-in period extending until October 30, 2027. This extended lock-in demonstrates a long-term commitment from the promoters, which could be viewed positively by the market as it aligns the promoters' interests with those of long-term shareholders.

As SMS Pharmaceuticals integrates this change in its equity structure, market participants will be watching closely to see how it influences the company's financial position and market performance in the coming quarters.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.62%	+1.25%	+8.71%	+20.75%	-5.44%	+237.51%

SMS Pharmaceuticals Limited (SMS Pharma) recently announced a significant change in its shareholding structure. Vistra ITCL (India) Limited, acting as a debenture trustee, has released a substantial number of pledged shares of the company. This move has led to a notable reduction in Vistra's encumbered shareholding in SMS Pharma.

Key Details of the Share Release

Aspect	Details
Shares Released	1,06,20,000 equity shares
Release Date	November 3, 2025
Pledged Shares Before Release	2,20,86,740 (23.58% of total share capital)
Pledged Shares After Release	1,14,66,740 (12.24% of total share capital)
Reduction in Encumbered Shareholding	11.34%

Impact on Shareholding Structure

The release of these pledged shares has significantly altered Vistra ITCL's position in SMS Pharmaceuticals. Prior to this action, Vistra held 23.58% of the company's total share capital in an encumbered form. Following the release, this figure has dropped to 12.24%, marking a substantial decrease in Vistra's pledged holdings.

Company's Share Capital

SMS Pharmaceuticals' total equity share capital remains unchanged at 9,36,52,030 shares, each with a face value of Rs. 1. This information is consistent with the shareholding pattern reported for the quarter ending September 2025.

Regulatory Compliance

Vistra ITCL filed this disclosure under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The company noted that while the primary responsibility for compliance lies with the lender and debenture holder, Vistra took this step as a precautionary measure in its capacity as a security and debenture trustee.

Additional Corporate Updates

SMS Pharmaceuticals has scheduled an Investor's Conference Call for November 11, 2025, at 11:00 am IST. This call will discuss the company's financial results and performance for the second quarter and half-year ended September 30, 2025. The Q2 and H1 FY26 results are set to be announced on November 8, 2025.

This development in SMS Pharmaceuticals' shareholding structure, particularly the significant reduction in pledged shares, may be of interest to investors and market analysts monitoring the company's financial health and ownership patterns.